The Use of Oracea and Epiduo Forte in Severe Acne Patients

Summary

This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications.

Timeline

Start

2018-03-19

Primary completion

2018-11-01

Completion

2019-01-04

Drugs

Indications